News | August 15, 2024
Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
India Business grew by 11.9% YoY to Rs. 1196.2 crore
India Business grew by 11.9% YoY to Rs. 1196.2 crore
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Our centers are performing as expected or even better
Expect the international business including CDMO business to pick-up in the second half of the financial year
Strong topline growth driven by solid performance across key brands.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Subscribe To Our Newsletter & Stay Updated
